SS offers a special opportunity for an antibody-based therapeutic intervention because of its high expression of the newly characterized oncogene tumor necrosis factor receptor 2 (TNFR2) on tumor cells [3], as well as on Treg cells in the tumor microenvironment [4–9]. The gene discussed is TNFRSF1B; the disease is neoplasm.